The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.

The present invention provides a compound or a method for treating an RNA viral infection in a human, particularly COVID-19. The compound is a certain tricyclic compound.

The present invention provides a compound or a method for treating an RNA viral infection in a human, particularly COVID-19. The compound is a certain tricyclic compound.

The present invention relates to electrospun fibers comprising i) a hydrophilic polymer that is soluble in a first solvent, ii) a bioadhesive substance that is slightly soluble in said first solvent, iii) optionally, a drug substance.

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: ##STR00001##

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: ##STR00001##

An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

Compositions comprising at least one NEK7 protein and a NEK7 small molecule inhibitor compound comprising at least one of the following features: (i) a hinge-binding element comprising at least one hydrogen donor and at least one hydrogen acceptor, (ii) a flexible linker, (iii) a urea linker, or (iv) a hydrophobic back pocket group. Methods associated with preparation and use of such NEK7 inhibitors, pharmaceutical compositions comprising such NEK7 inhibitors and methods to prevent diseases or disorders (e.g., via modulation of NLRP3 inflammasome activity) are also provided.